Provided by Tiger Fintech (Singapore) Pte. Ltd.

MIRXES-B

30.000
+6.70028.76%
Volume:9.18M
Turnover:274.94M
Market Cap:8.29B
PE:- -
High:31.950
Open:29.000
Low:29.000
Close:23.300
Loading ...

Company Profile

Company Name:
MIRXES-B
Exchange:
SEHK
Establishment Date:
2014
Employees:
352
Office Location:
2 Tukang Innovation Grove,#09-02 JTC MedTech Hub,Singapore,Singapore
Zip Code:
618305
Fax:
- -
Introduction:
MiRXES Holding Company Limited is a micro ribonucleic acid (miRNA) technology company specializing in early cancer detection and precision medicine. It develops and commercializes accurate, non-invasive, and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases. Its segments include Infectious diseases and Early detection and precision multi-omics. Its solutions include cancer screening; clinical sequencing; cancer treatment selection, and infectious diseases. Its core product (namely, GASTROClear), two other commercialized products (namely, LUNGClear and Fortitude), and six product candidates at pre-clinical stage. GASTROClear is a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening. LUNGClear, its lung cancer screening product candidate, is a detection panel consisting of miRNA biomarkers discovered and verified in multi-center studies. It offers complete COVID-19 testing solutions.